Condition: Atopic Dermatitis · Sponsor: Shanghai Mabgeek Biotech.Co.Ltd
This study was designed to reflect the safety pharmacokinetics and preliminary efficacy of MG-K10 Humanized Monoclonal Antibody Injection in adolescent patients 12-18 weeks of age with moderate to severe atopic dermatitis, administered every 2 or 4 weeks for 8 weeks
This description comes directly from the study's public registry record.
xiaofeng Cai · 02151371305 · xiaofeng.cai@mabgeek.com
Always discuss trial participation with your own doctor first.
| Hangzhou First People's Hospital; | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06765005